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Abstract The aim of the present study was to conduct a
meta-analysis of the effectiveness of tofacitinib, a novel oral
Janus kinase inhibitor, recently approved for the treatment of
active rheumatoid arthritis in patients who have failed previ-
ous treatment with methotrexate (MTX) or other disease-
modifying antirheumatic drugs (DMARDs). A systematic
literature search was conducted in PubMed, EMBASE,
Cochrane Library, and other databases till 3 May 2013. All
included studies were analyzed with the use of the Review
Manager 5.1.0. software according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement protocol. Nine randomized
controlled trials (RCTs) comparing tofacitinib with placebo
were identified. Two of them additionally provided the com-
parison with adalimumab. However, only eight RCTs met
the inclusion criteria for the meta-analysis. The overall re-
sults of the meta-analysis showed that tofacitinib provided a
statistically significant improvement according to the re-
sponse criteria (ACR20/50/70) after 12 weeks of treatment
when compared to placebo (p<0.00001). Moreover, it was
demonstrated that tofacitinib was significantly superior to
adalimumab in achieving the ACR50 response criteria at
week 12 (p=0.003). For the safety analysis, there were no
statistically significant differences between tofacitinib-,
adalimumab-, and placebo-treated patients in respect to the
risk of serious adverse events or treatment discontinuation
due to adverse reactions (p>0.05). The findings of this
systematic review with meta-analysis indicate that tofacitinib
monotherapy or with background methotrexate provides ear-
ly statistically significant and clinically important improve-
ment in rheumatoid arthritis symptoms and has an acceptable
safety profile comparable to that of placebo. The results of
the present meta-analysis show that the frequency of serious
adverse events was not increased after tofacitinib treatment.
In addition, tofacitinib might provide an effective treatment
option compared to intravenous or subcutaneous biological
DMARDs, as suggested by the result of the comparison
made regarding tofacitinib vs. adalimumab ACR50 response
rate.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by systemic, destructive, and progressive in-
flammatory polyarthritis, driven by immune system
dysregulation. RA affects approximately 1 % of the world
population and, if inadequately treated, leads to pain, swell-
ing, and progressive destruction of joints, with resulting
disability, substantial loss of functioning, and mobility or
work incapacity, decrease in quality of life, or reduction of
life expectancy [1–3]. Traditional disease-modifying anti-
rheumatic drugs (DMARDs) have become the cornerstone
of treatment for RA, with methotrexate (MTX) being most
commonly used in clinical practice as monotherapy or in
combination with other drugs [2, 3]. However, patients with
an inadequate response to the treatment with conventional
DMARDs or MTXmight be treated with biological response
modifiers targeting tumor necrosis factor (TNF) and
P. Kawalec (*) :A. Pilc
Drug Management Department, Institute of Public Health, Faculty
of Health Sciences, Jagiellonian University, 20 Grzegorzecka St.,
31-531 Kraków, Poland
e-mail: pawel.kawalec@uj.edu.pl
P. Kawalec :A. Mikrut :N. Wiśniewska
Centrum HTA Sp. z o.o. Sp. k, Kraków, Poland
A. Pilc
Department of Neurobiology, Institute of Pharmacology, Polish
Academy of Sciences, Kraków, Poland
Clin Rheumatol (2013) 32:1415–1424
DOI 10.1007/s10067-013-2329-9
interleukins (IL-6, IL-1), which play a pivotal role during the
pathological processes active in RA and with biological
agents targeting T and B cells [3, 4]. Biological DMARDs
(e.g., TNF inhibitors, abatacept, rituximab) are more effica-
cious than traditional DMARDs (e.g., methotrexate,
sulfasalazine) in controlling joint damage and significantly
improve physical function and quality of life [5]. Moreover,
the combination of conventional and biological DMARDs
may provide a faster resolution of the inflammatory process
and may increase the response rate [4]. Although the intro-
duction of biological agents with different immunological
targets into clinical routine has been associated with a sig-
nificant progress in RA treatment, a substantial proportion of
patients do not achieve appropriate disease control and some
of them discontinue therapy due to acquired therapeutic
resistance or adverse events [3]. For this reason, the search
for new molecules with a better risk-to-benefit ratio is ongo-
ing and, furthermore, inhibitors of signal transduction via the
intracellular pathways of inflammation are now in develop-
ment. The cytokines involved in immune regulation play
crucial roles in the pathogenesis of RA, and members of
the Janus kinase (JAK) family are essential for such signal
transduction. Tofacitinib is a novel selective inhibitor of
JAKs investigated as a targeted immunomodulator and a
disease-modifying therapy for RA [5]. Tofacitinib has al-
ready been approved by the FDA for adult patients with
moderately to severely active RA who have had an inade-
quate response or intolerance to methotrexate [6]. It might be
used as monotherapy or in combination with methotrexate or
other synthetic DMARDs. The drug is currently under reg-
ulatory review in Europe and Japan [3].
The aim of this systematic review with meta-analysis was
to evaluate the efficacy and safety of tofacitinib orally ad-
ministered to patients with active RA in whomMTX or other
DMARDs produced an inadequate response or intolerance.
Materials and methods
This systematic review was performed according to the
methods and recommendations from the Cochrane handbook
[7], and the meta-analysis was performed according to the
Preferred Reporting Items for Systematic Reviews andMeta-
analyses (PRISMA) Statement protocol, as described else-
where [8].
Eligibility criteria
Randomized controlled trials (RCTs) or abstracts published
in peer-reviewed journals, evaluating the use of tofacitinib vs.
placebo or adalimumab for the treatment of adult (≥18 years of
age) patients diagnosed with active RA in whom MTX,
DMARDs, or TNF inhibitors caused an inadequate response
or intolerance, were included in the analysis.
Data sources
Primary studies were identified by searching the electronic
databases (PubMed, EMBASE, Cochrane Central Register
of Controlled Trials) and register of clinical trials (www.
clinicaltrials.gov) for unpublished or ongoing trials and by
scanning the lists of references from the identified studies or
review articles. The websites of the European League
Against Rheumatism and American College of Rheumatol-
ogy were additionally searched for relevant information
concerning the clinical trials. Cochrane Database of System-
atic Reviews, DARE, PubMed, and EMBASE databases
were also searched for review articles. The search was
conducted till 3 May 2013.
Search strategy
Searches for primary studies were restricted and based on
appropriate MeSH and EMTREE terms that met the require-
ment: rheumatoid arthritis and the intervention—tofacitinib,
combined with Boole’s logical operators (Table 1). The
applied limits included human subjects and English, French,
and German languages. The full-text articles were preferred
because of opportunity to verify the reliability of potentially
useful studies, but due to the lack of certain results in the full-
text papers, we extracted the necessary data from the register
of controlled trial.
Study selection
The search and eligibility assessments were performed inde-
pendently by two reviewers (A.M., N.W.). Disagreements
were resolved by consensus, and when needed, a third re-
viewer acted as an adjudicator (P.K.). All titles were
screened, potential abstracts were read, and possible articles
were retained and their full text was critically reviewed.
Studies fulfilling the eligibility criteria were included in the
meta-analysis.
Data collection process
Data were extracted from the included studies by a single
reviewer using a standard data extraction form, and then,
they were checked by a second reviewer. Essential informa-
tion from each trial was collected: study design, characteris-
tics of participants, intervention and dosing regimen, con-
comitant therapy, duration of treatment, and clinical out-
comes. All studies were also scored by two independent
reviewers in accordance to the Jadad scale [9].
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Outcomes
The response rate to treatment with tofacitinib assessed
according to the American College of Rheumatology
(ACR) criteria [10] was the primary measure of outcomes.
These definitions included different variables, such as ten-
der and swollen joint counts, patient’s assessment of global
pain, physician’s assessment of disease activity, Health
Assessment Questionnaire (HAQ), and laboratory parame-
ters (either the C-reactive protein level or the erythrocyte
sedimentation rate). We also evaluated status of patients’
physical function with the use of the Health Assessment
Questionnaire—Disability Index (HAQ-DI). Safety was
evaluated based on the proportion of patients who experienced
serious adverse events (SAEs) or discontinued the treatment
due to adverse events.
Statistical analysis
Efficacy and safety were analyzed using dichotomous data.
The beneficial impact of the intervention was expressed as
the relative benefit (RB, described as the risk ratio or relative
risk [RR] presented in the graphs due to specific labeling of
the measurement of the effect in the statistical analysis soft-
ware) with 95 % confidence intervals (CIs). Adverse events
were summarized with RR. The results obtained from sepa-
rate trials were combined using appropriate methods of
meta-analysis. The inverse variance in Mantel–Haenszel or
DerSimonian–Laird effects model was used according to the
data input and heterogeneity of test results. The results for
sufficiently similar outcomes and homogenous data (deter-
mined by the degree of clinical and statistical heterogeneity)
were pooled. The clinical heterogeneity was assessed by
examining the characteristics of the featured studies, whereas
the statistical heterogeneity was assessed using the chi-
square test, with the significance set at p=0.10. Relative
parameters were calculated using the fixed effects model
when the statistical heterogeneity was not detected, and the
random effects model was used when heterogeneity was
present (p<0.10). All statistical tests and creations of forest
plots were carried out using the Review Manager version
5.1.0. software.
Results
Selection process and quality and characteristics
of the included studies
Of the 65 articles retrieved after the initial search, 15 selected
studies were reevaluated on the basis of full text and six were
not eligible. Also, one additional study was identified after
the search of lists of references in review articles, and finally,
ten references describing nine RCTs fulfilled the inclusion
criteria [11–20] but only eight RCTs met the inclusion
criteria for the meta-analysis [11–17, 20] (Fig. 1).
The characteristics of the included studies are described in
Table 2. All of them were randomized, double-blind,
placebo-controlled, and multicentre trials. Eight RCTs were
described in nine full-text papers published in peer-reviewed
journals [11–19]. One study [20] was available only in
abstract form, but the data were included in the meta-
analysis though as a lower grade evidence. A majority of
the randomized studies scored ≥3 points on the Jadad scale,
indicating a moderate or high methodological quality. Only
phase III trials had clearly described methods of randomiza-
tion [13–16]. All phase II trials scored three points due to a
lack of description of randomization and blinding methods.
No published articles mentioned an allocation concealment
in the studies. The quality of one RCT [20] could not be
accurately estimated due to a lack of the full-text version;
however, the study was double-blinded.
Patients in all included studies had active RA diagnosed
on the basis of the ACR 1987 revised criteria [21], with
an inadequate response to previous MTX monotherapy
[11–13, 15], anti-TNF agents [14], or generally nonbiological/
biological DMARDs [16–20] or to discontinued therapy due
to unacceptable toxicity from these drugs. All of the included
studies compared tofacitinib with placebo, and additionally,
two trials provided the comparison with adalimumab. In phase
II studies, multiple dosages of tofacitinib (1, 3, 5, 10, 15 mg
Table 1 MeSH subject headings and EMTREE keywords used in constructed search strategy for primary studies (last updated 3 May 2013)
Keywords (combined with Boole’s logical operator, OR)
Medical condition: rheumatoid arthritis; rheumatic arthritis; chronic polyarthritis; rheumarthritis; rheumatism
Intervention: tofacitinib; tasocitinib; xeljanz; CP 690,550; CP690550; CP-690550; CP 690550; CP-690,550; cp690550-10; cp690550 10
Methodological
limits:
PubMed: Humans, Randomized Controlled Trial, Clinical Trial, Controlled Clinical Trial; EMBASE: Humans, Controlled
Clinical Trials, Randomized Controlled Trial, Embase only; Cochrane Central Register of Controlled Trials: No limits
applied; word variations have been searched
Language limits: PubMed, EMBASE: English, French, German
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twice a day) were assessed, but in phase III trials, doses of 5
and 10 mg twice a day (bid) were selected as optimal for
evaluation. In the eligible studies, tofacitinib was used con-
comitantly with stable doses of an MTX background [11–15]
or was given as monotherapy [16–20]; however, drugs other
than DMARDs were generally permitted in both subgroups
(e.g., acetaminophen, nonsteroidal anti-inflammatory drugs,
corticosteroids). Duration of treatment ranged from 6 to
48 weeks.
Meta-analysis
We performed the meta-analysis of eligible RCTs that
compared tofacitinib with placebo or adalimumab. For
comparisons, we extracted data where tofacitinib was
used at the recommended dose for the commercially
marketed product (5 mg twice a day) based on FDA
approval [6]. The response rates based on the ACR
criteria (ACR20/50/70) were the efficacy endpoints. An
ACR20 response was defined as at least 20 % improve-
ment in both the tender joint count and the swollen joint
count and at least 20 % improvement in three of five other
core set measures: patient’s assessment of pain, patient’s
global assessment of disease activity, physician’s global
assessment of disease activity, patient’s assessment of
physical function, or acute-phase reactant value. For
ACR50 and ACR70, patients had 50 and 70 % improve-
ment, respectively, according to the above-mentioned
criteria [10]. An additional efficacy endpoint, i.e., physi-
cal function status measured by the HAQ disability index,
was reported in the studies as the mean change from
baseline in the HAQ-DI score or the percentage of pa-
tients who had reductions in the score of at least 0.22 or
0.30 points, indicating improvement of physical function.
Finally, we evaluated only the dichotomous data because
of their greater availability within the publications. For
safety assessment, we analyzed the incidence of SAEs and
the risk of treatment discontinuation due to adverse events.
The analyses were performed in two subgroups: for studies
assessing tofacitinib used in combination with MTX back-
ground and for studies on tofacitinib used as monotherapy.
The data for efficacy and safety evaluation were extracted at
week 12. Therefore, the results of the studies [18, 19] lasting
only for 6 weeks of treatment could not be included in the
meta-analysis.
A meta-analysis of the efficacy of tofacitinib vs. placebo
ACR response rate
All eight eligible RCTs evaluated the clinical response to
treatment according to the ACR criteria; five studies
[11–15] dealt with the efficacy of tofacitinib in compari-
son with placebo, both given concomitantly with stable
doses of MTX and three studies [16, 17, 20] compared
tofacitinib with placebo without the background of MTX
or other DMARDs. The overall result of the meta-analysis
demonstrated that tofacitinib was significantly superior to
placebo in achieving the ACR20 improvement criteria
after 12 weeks of treatment (RBrandom, 0.43; 95 % CI,
0.34 to 0.55; p<0.00001). ACR20 responses are presented
in Fig. 2. ACR50 responses within 12 weeks of treatment
with tofacitinib compared to placebo showed that the
relative benefit (RBfixed) was 0.29 (95 % CI, 0.23 to
0.37; p<0.00001). A total of 30 % of the tofacitinib-
treated patients achieved an ACR50 response compared
to 10 % of patients receiving placebo, irrespective of
backbone therapy. The RBfixed of achieving ACR70 was
0.19 (95 % CI, 0.12 to 0.29; p<0.00001) and 15.3 % of
patients receiving tofacitinib vs. 2.1 % of the control
group achieved this ACR response, indicating an absolute
benefit of 13.2 %.
Results of the analysis in subgroups showed that the
probability of ACR20/50/70 response to treatment was
significantly higher for both tofacitinib in combination
with MTX and tofacitinib monotherapy when compared
to placebo.
Duplicates removed: 9
Studies included in the quantitative synthesis: 8 RCTs
Studies included in the systematic review: 9 RCTs described in 10 
reference papers (and additionally in clinical trial register)
Excluded after reviewing 
full-text (N=6) because:
- pharmacokinetic study: 4
- secondary analysis of an 
included study (not the 
outcome of interest): 2
Total number of 
hits in additional 
sources: 27
Total number of hits in main databases: 38: 
PubMed - 13; Embase - 15; Cochrane -10
Results of hand searching 
of reference lists: 1
Excluded because title and 
abstract revealed 
not appropriate: 41
Studies retrieved for evaluation 
based on full-text paper: 15
Potentially relevant papers and 
screened for retrieval: 56
Fig. 1 PRISMA flow diagram for identification and selection of stud-
ies included in the systematic review and meta-analysis
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HAQ-DI
The rate of clinically significant improvement estimated by
HAQ-DI response was based on the results from two studies
[11, 14] assessing tofacitinib combined with MTX and from
two studies [16, 17] concerning monotherapy. The overall
result of meta-analysis showed that tofacitinib provided a sta-
tistically significant benefit compared to placebo in regard to
improvement of physical function (RBfixed, 0.55; 95%CI, 0.45
to 0.67; p<0.00001). The difference was significant across two
subgroups, irrespective of concomitant therapy (p≤0.0001).
A meta-analysis of the safety of tofacitinib vs. placebo
Risk of serious adverse events
Data on the incidence of SAEs were available in four studies
[11, 13–15] on the comparison of tofacitinib with placebo
both given concomitantly withMTX and in three studies [16,
17, 20] concerning tofacitinib or placebo given as
monotherapy (Fig. 3). There was no significant difference
in the frequency of serious AEs between tofacitinib and
placebo during 12 weeks of treatment (RRrandom, 0.81;
95 % CI, 0.31 to 2.14; p=0.67). In the subgroup analysis,
stratifying RTCs by concomitant exposure to MTX, the
differences between the tofacitinib and placebo were not
statistically significant either (p=0.68 and p=0.28, respec-
tively); however, comparing the subgroup results, the con-
comitant MTX therapy seemed to increase the risk of SAEs
in tofacitinib-treated patients.
Treatment discontinuation due to adverse events
In regard to the risk of withdrawal of patients from therapy
due to any adverse events during 12 weeks of treatment, the
overall result showed no statistically significant difference
between tofacitinib vs. placebo (RRfixed, 1.14; 95 % CI, 0.72
to 1.80; p=0.57). However, the results of subgroup analysis
Table 2 Characteristics of the included studies
Author and year of
publication [ref.],
design
Population Dosage and schedule, and duration of treatment and
follow-up
No. of patients (for efficacy)
Tanaka 2011 [11],
RCT phase II
Active RAwith an inadequate
response to MTX alone
(Japanese patients only)
Tofacitinib 1, 3, 5, or 10 mg bid or placebo; stable
background MTX; 12 weeks
Tofacitinib 5 mg bid,
N=27; placebo, N=28
Kremer 2012 [12],
RCT phase II
Active RAwith an inadequate
response to MTX alone
Tofacitinib 1, 3, 5, 10, or 15 mg bid or 20 mg/daily or
placebo; stable background MTX; 24 weeks (after week
12, nonresponder placebo [as well as tofacitinib 1 or 3 mg
bid and 20 mg/daily]-treated patients were advanced to
tofacitinib)
Tofacitinib 5 mg bid,
N=71; placebo, N=69
van Vollenhoven
2012 [13], RCT
phase III
Active RAwith an inadequate
response to MTX alone
Tofacitinib 5 or 10 mg bid or placebo or adalimumab 40 mg
once every 2 weeks; stable background MTX; 48 weeks
(after week 12, nonresponder placebo-treated patients
were advanced to tofacitinib)
Tofacitinib 5 mg bid,
N=204; placebo, N=108;
adalimumab, N=204
Burmester 2013 [14],
RCT phase III
Active RAwith an inadequate
response or intolerance to
TNFi and MTX
Tofacitinib 5 or 10 mg bid or placebo; stable background
MTX; 24 weeks (after week 12, placebo-treated patients
were advanced to tofacitinib)
Tofacitinib 5 mg bid,
N=133; placebo, N=132
van der Heijde 2013
[15], RCT phase
III
Active RAwith an inadequate
response to MTX
Tofacitinib 5 or 10 mg bid or placebo; stable background
MTX; 48 weeks (after week 12, nonresponder placebo-
treated patients were advanced to tofacitinib)
Tofacitinib 5 mg bid,
N=321; placebo, N=160
Fleischmann 2012
[16], RCT phase
III
Active RAwith an inadequate
response or intolerance to
DMARDs
Tofacitinib 5 or 10 mg bid or placebo; monotherapy;
24 weeks (after week 12, placebo-treated patients were
advanced to tofacitinib)
Tofacitinib 5 mg bid,
N=243; placebo, N=122
Fleischmann 2012
[17], RCT phase II
Active RAwith an inadequate
response or intolerance to
DMARDs
Tofacitinib 1, 3, 5, 10, or 15 mg bid or placebo or
adalimumab 40 mg once every 2 weeks; monotherapy;
24 weeks (after week 12, nonresponder placebo [as well
as tofacitinib 1 or 3 mg bid]-treated patients were
advanced to tofacitinib)
Tofacitinib 5 mg bid,
N=49; placebo, N=59;
adalimumab, N=53
Kremer 2009 [18],
Coombs 2010
[19], RCT phase II
Active RAwith an inadequate
response or intolerance to
DMARDs
Tofacitinib 5, 15, or 30 mg bid or placebo; monotherapy;
6 weeks (followed up for an additional 6 weeks)
Tofacitinib 5 mg bid,
N=61; placebo, N=65
Tanaka 2011 (abs)
[20], RCT phase II
Active RAwith an inadequate
response to DMARDs
Tofacitinib 1, 3, 5, 10, 15 mg or placebo; monotherapy;
12 weeks
Tofacitinib 5 mg bid,
N=50; placebo, N=48
bid twice daily, DMARDs disease-modifying antirheumatic drugs, MTX methotrexate, RCT randomized controlled trial, TNFi tumor necrosis factor
inhibitors
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showed slight divergent trends but these findings did not
reach statistical significance. Similarly to the risk of SEAs,
it seemed that concomitant MTX could increase the risk of
treatment discontinuation due to an adverse event; however,
it is noteworthy that tofacitinib appears to have an acceptable
safety profile.
Study or Subgroup
1.1.1 with concomitant methotrexate
Burmester 2013 (14)
Kremer 2012 (12)
Tanaka 2011 (11)
van der Heijde 2013 (15)
van Vollenhoven 2012 (13)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.06; Chi² = 10.20, df = 4 (P = 0.04); I² = 61%
Test for overall effect: Z = 5.10 (P < 0.00001)
1.1.2 monotherapy
Fleischmann 2012 (16)
Fleischmann 2012 (17)
Tanaka 2011 (20)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.08; Chi² = 4.58, df = 2 (P = 0.10); I² = 56%
Test for overall effect: Z = 4.72 (P < 0.00001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.06; Chi² = 17.30, df = 7 (P = 0.02); I² = 60%
Test for overall effect: Z = 7.07 (P < 0.00001)
Test for subgroup differences: Chi² = 1.39, df = 1 (P = 0.24), I² = 27.9%
Events
32
23
4
42
28
129
33
13
7
53
182
Total
131
69
28
154
106
488
122
59
48
229
717
Events
55
36
26
174
119
410
145
29
37
211
621
Total
132
71
27
309
196
735
243
49
50
342
1077
Weight
14.7%
13.5%
5.1%
17.3%
15.4%
66.0%
16.3%
10.4%
7.4%
34.0%
100.0%
M-H, Random, 95% CI
0.59 [0.41, 0.84]
0.66 [0.44, 0.99]
0.15 [0.06, 0.37]
0.48 [0.37, 0.64]
0.44 [0.31, 0.61]
0.48 [0.36, 0.64]
0.45 [0.33, 0.62]
0.37 [0.22, 0.63]
0.20 [0.10, 0.40]
0.35 [0.23, 0.54]
0.43 [0.34, 0.55]
placebo tofacitinib Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours tofacitinib Favours placebo
Fig. 2 The effect of tofacitinib compared with placebo on 20 % improvement according to the American College of Rheumatology criteria (ACR20)
at week 12
Study or Subgroup
3.2.1 with concomitant methotrexate
Burmester 2013 (14)
Tanaka 2011 (11)
van der Heijde 2013 (15)
van Vollenhoven 2012 (13)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.33; Chi² = 4.54, df = 3 (P = 0.21); I² = 34%
Test for overall effect: Z = 0.41 (P = 0.68)
3.2.2 monotherapy
Fleischmann 2012 (16)
Fleischmann 2012 (17)
Tanaka 2011 (20)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.51; Chi² = 3.91, df = 2 (P = 0.14); I² = 49%
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.74; Chi² = 11.29, df = 6 (P = 0.08); I² = 47%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi² = 1.33, df = 1 (P = 0.25), I² = 24.8%
Events
2
1
12
12
27
1
0
2
3
30
Total
133
28
321
204
686
243
49
52
344
1030
Events
6
0
5
2
13
6
2
1
9
22
Total
132
28
160
108
428
122
59
52
233
661
Weight
17.6%
7.4%
24.2%
18.7%
67.9%
13.0%
7.9%
11.2%
32.1%
100.0%
M-H, Random, 95% CI
0.33 [0.07, 1.61]
3.00 [0.13, 70.64]
1.20 [0.43, 3.34]
3.18 [0.72, 13.94]
1.22 [0.47, 3.20]
0.08 [0.01, 0.69]
0.24 [0.01, 4.88]
2.00 [0.19, 21.38]
0.33 [0.05, 2.44]
0.81 [0.31, 2.14]
tofacitinib placebo Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours tofacitinib Favours placebo
Fig. 3 The effect of tofacitinib compared with placebo on the risk of serious adverse events during 12 weeks of treatment
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Ameta-analysis of the efficacy of tofacitinib vs. adalimumab
Data on the efficacy of tofacitinib in comparison with
adalimumab (a TNF inhibitor, TNFi) were available only in
two placebo-controlled trials [13, 17]. In one study [13],
tofacitinib and adalimumab were given concomitantly with
MTX, and in the other study [17], the investigated agents
were used in monotherapy. Because of the limited number of
trials, the included patients were not subdivided according to
a background therapy. We compared data on tofacitinib at a
dose of 5 mg bid and adalimumab administered subcutane-
ously at 40 mg once every second week.
ACR response rate
The relative benefit (RBrandom) of 20 % improvements
according to the ACR treatment response criteria at week
12 was 0.79 (95 % CI, 0.52 to 1.18; p=0.25) without a
significant difference between tofacitinib and adalimumab.
Likewise, the ACR70 response rate showed no statistically
significant difference between the antirheumatic agents
(RBfixed, 0.62; 95 % CI, 0.36 to 1.07; p=0.08). What is
important, based on the ACR50 criterion, is that tofacitinib
was found to be significantly superior to adalimumab
(RBfixed, 0.65; 95 % CI, 0.49 to 0.87; p=0.003). ACR50
responses are presented in Fig. 4. A total of 34.7 % of the
tofacitinib-treated patients achieved a 50 % improvement
compared to 22.6 % of patients receiving adalimumab, indi-
cating an absolute benefit of 12.1 %.
A meta-analysis of the safety of tofacitinib vs. adalimumab
Risk of serious adverse events and treatment discontinuation
due to adverse events
A meta-analysis on the basis of two RCTs [13, 17] revealed
no statistically significant difference between tofacitinib and
adalimumab in the frequency of SAEs during 12 weeks of
treatment (RRfixed, 2.00; 95 % CI, 0.78 to 5.13; p=0.32).
Similarly, the risk of discontinuation of treatment because of
adverse events did not differ significantly between the inves-
tigated drugs (RRfixed, 1.17; 95 % CI, 0.56 to 2.45; p=0.68).
Discussion
To our knowledge, this is the first meta-analysis and the most
up-to-date systematic review evaluating the efficacy of
tofacitinib in RA. What is more is that its methodology
followed the methods described in the Cochrane handbook
and the meta-analysis was performed according to the
PRISMA Statement protocol. The applied search strategy
revealed all of the relevant published and unpublished arti-
cles. Ten papers reporting on nine RCTs published between
2009 and May 2013 were included in the systematic review,
and eight trials were included in the meta-analysis. It should
be noted that during study selection, we excluded one open-
label phase I study [22] which investigated the effects of
MTX on the pharmacokinetics of tofacitinib in patients with
RA.
The results of the meta-analysis are relevant to the popu-
lation of adult patients with active moderate-to-severe RA
who failed on or had an inadequate response or intolerance
to MTX, other DMARDs, or TNF inhibitors. Although con-
ventional DMARDs (e.g., methotrexate, leflunomide,
sulfasalazine) are generally offered as first-line treatment
for the patients with RA, biological DMARDs with usually
a TNFi administered as a first choice therapy [4, 23, 24]
remain an established treatment option for patients with
suboptimal response or intolerance to synthetic DMARDs.
A lot of studies have demonstrated the efficacy of the anti-
TNF therapy in RA [3]. The results of meta-analysis [23] on
the basis of seven RCTs comparing the use of infliximab and
placebo in RA patients concomitantly using methotrexate
showed significantly higher efficacy of infliximab relative
to a control in regard to achieving ACR20, ACR50, and
ACR70 values during 14–30 weeks of treatment. Aaltonen
et al. [24] performed a meta-analysis evaluating the effec-
tiveness of five anti-TNF agents (adalimumab, infliximab,
certolizumab, golimumab, and etanercept) compared to ei-
ther MTX and placebo or placebo alone in the treatment of
RA. Their meta-analysis demonstrated that TNFi was more
efficacious than placebo but comparable to MTX. Moreover,
the combination of TNFi and MTX was found to be superior
to either MTX or TNFi alone. TNFi given alone or added to
MTX was not associated with an increased risk of serious
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adverse events or any infections when compared with place-
bo or MTX [24]. Additionally, in the network meta-analysis
[25] evaluating the efficacy of EU-licensed biological
DMARDs for RA treatment (apart from TNFi, also rituxi-
mab or tocilizumab and abatacept), it was shown that all
combinations of biological and traditional disease modifiers
(except rituximab) were significantly better than convention-
al DMARDs in improving ACR20/50/70 outcomes in pa-
tients with inadequate response to prior MTX monotherapy.
Almost all biological DMARDs approved for the treat-
ment of RA over the past decade require inconvenient,
intravenous, or subcutaneous administration associated with
specific concerns, including immunogenicity and infusion or
injection site reactions; moreover, they are relatively expen-
sive [3, 6]. Unlike these agents, tofacitinib is an orally
administered and easy-to-synthesize small molecule affect-
ing intracellular signal transduction of cytokines involved in
the inflammatory process in RA [5, 6]. In this respect,
tofacitinib provides an innovative oral therapeutic option
for patients with moderately to severely active RAwho failed
to respond or were intolerant to traditional DMARDs and/or
TNFi, as it targets the multiple pathogenic cytokines and,
therefore, may have a broader spectrum of activity than other
biological agents, such as TNFi acting against single inflam-
matory cytokines [3]. However, at the moment, it is crucial to
determinate the comparative efficacy of tofacitinib vs. bio-
logical DMARDs, particularly TNFi. We provided a direct
comparison of tofacitinib and adalimumab on the basis of
two RCTs [13, 17], but other head-to-head trials are still
lacking. Although these studies were not designed or
powered to compare accurately the efficacy of tofacitinib
with that of adalimumab, the result of our meta-analysis,
indicating the superiority of tofacitinib over adalimumab in
respect to ACR50 improvement, might lead to an assumption
that the currently tested JAK inhibitor could provide better
benefits than the currently used biological DMARDs, like
anti-TNF agents.
In the current meta-analysis based on phase II and III
studies, tofacitinib administered with MTX background or
as monotherapy showed an acceptable safety profile, com-
parable to placebo and adalimumab in respect to the risk of
SAEs and discontinuations due to any adverse events.
Concerning safety issues, according to integrated safety data
[6], infections, including upper respiratory tract infections
and nasopharyngitis, were the most frequent adverse events
observed with tofacitinib, and pneumonia and herpes zoster
were the most common adverse events leading to discontin-
uation of treatment. Since all biological agents used in the
treatment of RA interfere with the immune system and may
cause specific adverse events, which can lead to a discontin-
uation of treatment [26], JAK inhibitors also were expected
to have a higher degree of risk for immunosuppression, and
special attention is being paid to the incidence of infections
and malignancies [3]. One of the most recent meta-analyses
[27] evaluated the safety of RA treatment with various novel
protein kinase inhibitors, like JAK, SyK, p38, and c-Kit
inhibitors. For JAK inhibitors, the assessment of safety
encompassed the same studies that we had included in the
current meta-analysis with additional results from phase I
study [22]. It was shown that serious infections and malig-
nancies were not significantly more frequent in tofacitinib-
treated patients than in placebo groups. On the other hand, it
should be emphasized that sensitivity analysis just based on
full reports of trials concerning RAwith at least 12 weeks of
exposure revealed a significantly higher relative risk for
hypercholesterolemia in tofacitinib-treated patients com-
pared to placebo [27]. Nonetheless, as stated in the report
[6], the overall safety profile of tofacitinib, dosed at either 5
or 10 mg bid, was generally consistent with that observed in
patients treated with biological and nonbiological DMARDs.
There are a few limitations to our meta-analysis. The
analysis of the efficacy was mainly based on the response
rate according to the ACR (20/50/70) criteria. It should be
emphasized that this outcome is a composite endpoint, which
may be burdened with some limitations, such as unexpected
differences in the individual measures of each component.
However, despite the fact that we aggregated available data
only for HAQ-DI improvement, clinically significant im-
provements in functional and health status measured by
individual components of the ACR response criteria were
consistent throughout the studies. Moreover, in all included
studies, the response rates were measured according to the
ACR criteria that have been defined several years ago [10].
In the revision published in 2007, the American College of
Rheumatology suggested that the use of a new hybrid mea-
sure of RA response combining the ACR20, the ACR50, and
the ACR70 and a continuous score of the mean improvement
in core set measures would maximize the sensitivity to
change [28]; however, that hybrid measure was not applied
in the studies included in the current meta-analysis.
Another important factor is that the efficacy of tofacitinib
was assessed only for a dose of 5 mg bid, even though in the
included studies various dosages have been evaluated. Based
on the results of the tofacitinib development program that
investigated its use in the treatment of RA, balancing effica-
cy and safety data, the FDA approved only the dose of 5 mg
twice daily in monotherapy or in combination with MTX or
other nonbiological DMARDs. However, it has been con-
firmed that some patients might benefit from a dose increase
to 10 mg twice a day based on clinical response [6].
Though the duration of treatment in the included studies
ranged from 6 to 48 weeks, we based the meta-analysis on
the data extracted at week 12. Week 12 was chosen because
almost all the studies reported the results for this period, and
in some longer lasting trials, patients failing to meet
predefined treatment response criteria after 12 weeks of
1422 Clin Rheumatol (2013) 32:1415–1424
therapy were switched from the control group to active drug
or from the lower dosages to a higher dose of tofacitinib. The
applied method of imputation of the outcomes could intro-
duce a bias to the evaluation of the efficacy results. Although
four [12, 14, 16, 17] and two [13, 15] trials lasted up to 24
and 48 weeks, respectively, in part of them, data for efficacy
and safety outcomes for periods longer than 12 weeks were
not extractable without avoiding imputation analysis. How-
ever, we realize that the current meta-analysis would have
been powered if the efficacy and especially safety results had
been reported at longer time points.
Although the duration of treatment in the studies [18, 19]
was 6 weeks with an additional 6-week follow-up period, the
reported results were obtained at week 6; therefore, they
could not be aggregated with other studies’ outcomes
extracted at week 12. This study was the first conducted
dose-ranging RCT reporting on the efficacy and tolerability
of tofacitinib in patients with active RA in whom MTX or
TNFi caused an inadequate response or intolerability reac-
tions. Improvement in efficacy outcomes were seen in all
groups treated with various doses of tofacitinib. It can be
assumed that pooling the results from the studies [18, 19]
with other results extracted at 12 weeks of treatment would
not influence the overall favorable effect of tofacitinib ther-
apy despite the different treatment durations. It is worth to
emphasize that the long-term results from 48-week analysis
in the study [15] confirm findings seen previously in phase II
studies with shorter treatment periods [11, 12].
It should be noted that some publications did not provide
enough detailed and extractable data on the outcomes. For
this reason, information for some endpoints, mainly
concerning ACR50 or ACR70 [11–13, 15], was retrieved
as raw data from particular study results provided by the
register of clinical trials website. Selective outcome
reporting could therefore be a limitation in our meta-
analysis. However, we believe that this method would not
affect significantly the overall results.
In summary, the results of our meta-analysis have dem-
onstrated that tofacitinib provides a greater efficacy than
placebo, showing rapid, statistically significant, and clinical-
ly meaningful reductions in signs and symptoms of RA. In
addition, so far, tofacitinib seems to present comparable
efficacy in relation to adalimumab, but on the basis of one
analyzed outcome (ACR50), it can be assumed that this
agent has a greater potential to suppress disease activity than
TNFi; however, it needs to be confirmed in a larger number
of reliable studies. In the light of consistent efficacy across
the available RCTs, and manageable as well as predictable
adverse effects, the overall risk–benefit ratio of therapy with
tofacitinib in RA is favorable. However, there is still a need
for long-term post-marketing studies to define the effective-
ness of tofacitinib, especially in respect to its safety profile in
the real-world population of patients suffering from RA.
It should be noted that tofacitinib is the first-in-class JAK
inhibitor approved for RA treatment. Furthermore, tofacitinib
has already been investigated in clinical trials for other in-
dications including inflammatory bowel disease, psoriasis,
and dry eye syndrome and for the prevention of renal trans-
plant rejection, with promising preliminary results [5].
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